



SUMMARY OF ADNI Plasma INVENTORY

ADNI UPENN BIOMARKER CORE



1. Percentage of Subjects Providing Plasma per ADNI study phase

- a. Figure 1 page 4
- b. Table 1 page 5

2. Comparison of Prepared Aliquots from Originally Received Plasma Samples at BASELINE for all ADNI

- a. Figure 2a (BASELINE).....page 6
- b. Figure 2b (Yr 1 Follow-Up for ADNI 1)..... page 7
- c. Table 2ab page 8

3. Comparison of Currently Available Prepared Plasma Aliquots at BASELINE for all ADNI

- a. Figure 2c (BASELINE) page 9
- b. Figure 2d (Yr 1 Follow-Up for ADNI 1) page 10
- c. Table 2cd page 11

4. Number of Prepared Aliquots from Originally Received Plasma Samples at BASELINE and Follow-Up Visit for ADNI 1

- a. Figure 3a page 12
- b. Table 3a page 13

5. Number of Currently Available Prepared Plasma Aliquots at BASELINE and Follow-Up Visits for ADNI 1

- a. Figure 3b page 14
- b. Table 3b page 15

6. Number of Prepared Aliquots from Originally Received Plasma Samples for ADNI 2 Phase at BASELINE and Follow-Up Visits

- a. Figure 4a page 16
- b. Table 4a page 17

7. Number of Currently Available Prepared Plasma Aliquots for ADNI 2 at BASELINE and Follow-Up Visits

- a. Figure 4b page 18
- b. Table 4b page 19

8. Summary of CSF, Plasma, Serum, and Whole Blood Aliquots shipped to RARC-approved investigators

- a. Table/Figure 5 page 20

9. Graph and Table of Summary of Plasma Aliquots used for Luminex runs

a. Figure 6 and Table 6page 24

10. Percentage of Subjects Providing Plasma Samples per ADNI DOD visit

a. Figure 7page 25

b. Table 7 page 26

11. Number of Prepared Aliquots from Originally Received Plasma Samples for ADNI DOD at BL and Yr 1 Follow-Up Visits

a. Figure 8page 27

b. Table 8page 28

12. Number of Currently Available Prepared Plasma Aliquots for ADNI DOD at BL and Yr 1 Follow-Up Visits

a. Figure 9page 29

b. Table 9page 30

*** Note: BL = “Baseline”**

Subjects Providing Plasma at Baseline in each ADNI Study Phase (Graph)




Figure 1. Comparison by Percentage of subjects who provided plasma at Baseline for each ADNI Study Phase. The figure above compares the percentage of those enrolled that provided plasma samples at Baseline between ADNI 1, ADNI GO, and ADNI 2. As of **January 28th, 2016**, approximately 95.57% of those enrolled in ADNI 1 provided plasma samples at baseline compared to 93.38% of those enrolled in ADNI GO and 96.96% of those enrolled in ADNI 2.

* At least 96.96% (N = 765) of the 789 subjects enrolled in ADNI 2 have provided plasma samples at Baseline as of **January 28th, 2016**. This report also includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

Subjects Providing Plasma at Baseline in each ADNI Study Phase (Table)

Summary Table of Percentage of subjects providing plasma samples within each ADNI Study Phase

	Baseline(De-Novo)			Year 1 Follow-Up (De Novo)	
ADNI Group	Number of Subjects enrolled as of Jan. 28th, 2016	Number who provided PLA	% who provided PLA per ADNI group	Number who provided PLA	% who provided PLA per ADNI group
ADNI 1	822	787	95.57%	721	87.77%
ADNI GO	136	127	93.38%	115	84.56%
ADNI 2	789	765	96.96%	611	77.44%
Total	1747	1679	96.11%	1447	82.28%

Table 1. Summary Table of Percentage of subjects providing plasma samples within each ADNI Study Phase at Baseline and at 1 year Follow-Up. This is a summary table for Figure 1, detailing the number and percent of subjects providing plasma samples within each ADNI StudyPhase, as well as the number and percentage of those who provided plasma samples at 1 year follow-up as of **Jan. 28th, 2016**. “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that same study phase. This also includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

Prepared Aliquots from Originally Received Plasma Samples at Baseline for all ADNI (Graph)




Figure 2a. Comparison of the number of Prepared Aliquots from Originally Received Plasma Samples at Baseline for ADNI 1, GO, and 2. The graph above displays the frequency of originally received plasma aliquots and the number of subjects who have provided plasma samples at Baseline in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, 61 of the subjects enrolled in ADNI 1 originally provided between 6 to 10 plasma aliquots, compared to 12 subjects enrolled in ADNI GO and 44 subjects enrolled in ADNI 2.

Prepared Aliquots from Originally Received Plasma Samples at 1-yr Follow-Up for all ADNI (Graph)




Figure 2b. Comparison of the number of Prepared Aliquots from Originally Received Plasma Samples at 1-Year Follow-Up for ADNI 1, GO, and 2. The graph above displays the frequency of originally received plasma aliquots and number of subjects who have provided plasma samples at 1 year Follow-Up in ADNI 1, ADNI GO, and ADNI 2. The volume of each plasma aliquot is 0.5 ml. For example, 62 of the subjects enrolled in ADNI 1 have provided between 6 to 10 plasma aliquots, compared to 6 of the subjects initially enrolled in ADNI GO and 22 of the subjects initially enrolled in ADNI 2.

Summary Table of Prepared Aliquots from Originally Received Plasma Samples for all ADNI

Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase

Frequency of Originally Received Aliquots at BL and Yr 1 Follow-Up (De Novo)						
Number of Aliquots	ADNI 1		ADNI GO		ADNI 2	
	BL	Yr 1	BL	Yr 1	BL	Yr 1
0	0	0	0	0	0	0
1 to 5	15	11	4	0	6	4
6 to 10	61	62	12	6	44	22
11 to 15	208	154	41	24	165	148
16 to 20	463	444	59	71	477	379
21 to 25	40	49	11	14	62	43
26 to 30	0	1	0	0	11	15
Total	787	721	127	115	765	611

Table 2ab. Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase. Table 2 (above) corresponds to Figures 2a and 2b, detailing the number of subjects who have provided plasma samples at Baseline and at 1 year follow-up within each ADNI study phase (ADNI 1, GO, and 2). Again, “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that study phase. ADNI 1 “De Novo”, for example, indicates that 65 of the subjects initially enrolled in ADNI 1 provided between 6 and 10 plasma aliquots at Baseline, and likewise, there were 62 ADNI 1 subjects who provided between 6 and 10 plasma aliquots at the 1 year follow-up within ADNI 1.

Currently Available Prepared Plasma Aliquots at Baseline for all ADNI (Graph)




Figure 2c. Comparison of Available Prepared Plasma Aliquots at Baseline for ADNI 1, GO, and 2. The graph above displays the number of aliquots currently available from subjects who have provided plasma samples at Baseline in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, there are currently between 6 and 10 plasma aliquots available for 127 of the subjects from ADNI 1, compared to 12 subjects from ADNI GO and 43 subjects from ADNI 2.

Currently Available Prepared Plasma Aliquots at 1-yr Follow-Up for all ADNI (Graph)




Figure 2d. Number of Available Prepared Plasma Aliquots at 1 Year Follow-Up for ADNI 1, GO, and 2. The graph above displays the number of aliquots currently available from subjects who have provided plasma samples at 1-yr follow-up in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, there are currently between 6 and 10 plasma aliquots available for 84 of the subjects from ADNI 1, compared to 6 subjects from ADNI GO and 23 subjects from ADNI 2.

Summary Table of Currently Available Prepared Plasma aliquots for all ADNI

Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase

Frequency of Currently Available Aliquots at BL and Yr 1 Follow-Up (De Novo)						
Number of Aliquots	ADNI 1		ADNI GO		ADNI 2	
	BL	Yr 1	BL	Yr 1	BL	Yr 1
0	0	0	0	0	0	0
1 to 5	41	31	4	0	6	4
6 to 10	127	84	12	6	43	23
11 to 15	433	316	41	25	170	144
16 to 20	182	286	59	70	475	382
21 to 25	4	4	11	14	60	43
26 to 30	0	0	0	0	11	15
Total	787	721	127	115	765	611

Table 2cd. Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase. Table 2 (above) corresponds to Figures 2c and 2d, detailing the number of subjects who have provided plasma samples at Baseline and at 1 year follow-up within each ADNI study phase (ADNI 1, GO, and 2). Again, “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that study phase. ADNI 1 “De Novo”, for example, indicates that currently there are between 6 and 10 Baseline plasma aliquots for 127 of the subjects initially enrolled in ADNI 1, and likewise, there are currently between 6 and 10 plasma aliquots for 84 of the ADNI 1 subjects at the 1-year follow-up. Again, this includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

Prepared Aliquots from Originally Received Plasma Samples at Baseline and Follow-Up Visit for ADNI 1




Figure 3a. Comparison of the number of Prepared Aliquots from Originally Received Plasma Samples at Baseline and Follow-Up Visits within ADNI 1. The graph above displays the frequency of number of plasma aliquots provided by subjects who were initially enrolled in ADNI 1 and followed up within the ADNI 1 study phase. For example, of those enrolled in ADNI 1, we originally received between 6 and 10 plasma aliquots from 61 of the subjects who provided plasma at Baseline, compared to that of 62 subjects at 1-year follow-up, 43 subjects at 2-year follow-up, 35 subjects at 3-year follow-up, and 24 subjects at the 4-year follow-up.

Prepared Aliquots from Originally Received Plasma Samples at Baseline and Follow-Up Visits for ADNI 1 (Table)

Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1

ADNI 1 Originally Received Longitudinal Samples					
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4
0	0	0	0	0	0
1 to 5	15	11	10	12	5
6 to 10	61	62	43	35	24
11 to 15	208	1	136	102	75
16 to 20	463	4	402	269	141
21 to 25	40	49	32	31	16
26 to 30	0	1	0	0	0
31 to 35	0	0	0	0	0
36 to 40	0	0	0	0	0
41 to 45	0	0	0	0	0
46 to 50	0	0	1	0	0
Total	787	721	624	449	261

Table 3a. Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1. Table 3 (above) corresponds to Figure 3a, detailing the number of plasma aliquots that were originally received for subjects enrolled in ADNI 1 at Baseline as well as during the follow-up visits within the ADNI 1 study phase. Again, this includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

Currently Available Prepared Plasma Aliquots at Baseline and Follow-Up Visits for ADNI 1 (Graph)




Figure 3b. Number of Currently Available Prepared Plasma Aliquots at Baseline and Follow-Up Visits within ADNI 1. The graph above displays the frequency of number of currently available of plasma aliquots provided by subjects who were initially enrolled in ADNI 1 and followed up within the ADNI 1 study phase. For example, of those enrolled in ADNI 1, there are currently between 6 and 10 plasma aliquots available from 127 of the subjects who provided plasma at Baseline, compared to that of 84 subjects at 1-year follow-up, 49 subjects at 2-year follow-up, 35 subjects at 3-year follow-up, and 24 subjects at the 4-year follow-up.

Currently Available Prepared Plasma Aliquots at Baseline and Follow-Up Visits for ADNI 1 (Table)

Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1

ADNI 1 <u>Currently Available</u> Longitudinal Samples					
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4
0	0	0	0	0	0
1 to 5	41	31	21	12	5
6 to 10	127	84	49	35	24
11 to 15	433	316	265	102	75
16 to 20	182	286	276	269	141
21 to 25	4	4	12	21	16
26 to 30	0	0	1	0	0
31 to 35	0	0	0	0	0
36 to 40	0	0	0	0	0
41 to 45	0	0	0	0	0
46 to 50	0	0	1	0	0
Total	787	721	624	449	261

Table 3b. Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1. Table 3b (above) corresponds to Figure 3b, detailing the number of plasma aliquots that currently remain in our repository for subjects enrolled in ADNI 1 at Baseline as well as during the follow-up visits within the ADNI 1 study phase.

Prepared Aliquots from Originally Received Plasma Samples for ADNI 2 at BL and Follow-Up Visits (Graph)




Figure 4a. Comparison of the number of Prepared Aliquots from Originally Received Plasma Samples at Baseline and Follow-Up Visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO). The graph above displays the frequency of number of plasma aliquots provided by subjects enrolled in the ADNI 2 study phase at Baseline and at Follow-Up visits. Subjects who provided plasma samples at Baseline in ADNI 2 are those who were initially enrolled in ADNI 2. The follow-up visits here include subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO.

Prepared Aliquots from Originally Received Plasma Samples for ADNI 2 at BL and Follow-Up Visits (Table)

Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-overs from ADNI 1 and GO)

ADNI 2 Originally Received Longitudinal Samples (including Rollovers from ADNI 1 and GO)										
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9
0	0	0	0	0	0	0	0	0	0	0
1 to 5	6	4	10	4	6	6	1	0	0	1
6 to 10	44	22	43	41	24	11	8	4	8	3
11 to 15	165	148	136	160	86	48	45	47	34	4
16 to 20	477	379	402	219	135	139	143	111	57	19
21 to 25	62	43	32	13	10	20	16	13	12	2
26 to 30	11	15	0	0	0	1	1	1	1	0
31 to 35	0	0	0	0	0	0	0	0	0	0
36 to 40	0	0	0	0	0	0	0	0	0	0
41 to 45	0	0	0	0	0	0	0	0	0	0
46 to 50	0	0	1	0	0	0	0	0	0	0
Total	765	729	624	449	261	225	214	176	112	29

Table 4a. Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO). This is a summary table corresponding to Figure 4a, detailing the number of subjects who provided plasma samples at baseline in ADNI 2 (ADNI 2 enrollees only) as well as at follow-up visits (including subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO).

Currently Available Prepared Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Graph)




Figure 4b. Number of Available Prepared Plasma Aliquots at Baseline and Follow-Up Visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO). The graph above displays the frequency of number of plasma aliquots provided by subjects enrolled in the ADNI 2 study phase at Baseline and at Follow-Up visits. Subjects who provided plasma samples at Baseline in ADNI 2 are those who were initially enrolled in ADNI 2. The follow-up visits here include subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO.

Currently Available Prepared Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Table)

Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-overs from ADNI 1 and GO)

ADNI 2 <u>Currently Available</u> Longitudinal Samples (including Rollovers from ADNI 1 and GO)										
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9
0	0	0	0	0	0	0	0	0	0	0
1 to 5	41	31	21	12	5	6	1	0	0	1
6 to 10	127	84	49	35	24	11	8	4	8	3
11 to 15	433	316	265	102	75	48	46	47	34	4
16 to 20	182	286	276	269	141	139	142	111	57	19
21 to 25	4	4	12	31	16	20	16	13	12	2
26 to 30	0	0	1	0	0	1	1	1	1	0
31 to 35	0	0	0	0	0	0	0	0	0	0
36 to 40	0	0	0	0	0	0	0	0	0	0
41 to 45	0	0	0	0	0	0	0	0	0	0
46 to 50	0	0	1	0	0	0	0	0	0	0
Total	765	729	624	449	261	225	214	176	112	29

Table 4b. Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO). This is a summary table corresponding to Figure 4b, detailing the number of subjects who provided plasma samples at baseline in ADNI 2 (ADNI 2 enrollees only) as well as at follow-up visits (including subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO).

Table 5. Summary of CSF, Plasma, Serum, Whole Blood Aliquots shipped to RARC-approved investigators

Shipment Date	Principal Investigator	Project	Specimen Type	Specimen Number	Data Upload to ADNI/LONI
9/15/2015	Ian Sherriff, PI Araclon Biotech	A β 1-42 and A β 1-40	Plasma	784 ADNI1, GO, 2 longitudinal aliquot samples 759 PLA aliquots 25 Replicates	Data uploaded on 2/16/2016
3/17/2015	Jing Zhang, PI Harborview Medical Center, University of Washington School of Medicine	Total α -syn Ser129 Phosphorylated α -syn	CSF	*372 ADNI1 Baseline CSF aliquot samples *transferred from Geoff Baird 461 ADNI1, GO, 2 longitudinal aliquot samples 446 CSFs 15 Replicates	Study in Progress
9/23/2014	Dr. Kaj Blennow, PI Clinical Neurochemistry Lab	Tau Plasma	Plasma	595 ADNI1 aliquot samples 579 Baseline PLA 16 Replicates	Data uploaded on 8/4/2015
07/09/2014	Allan Levey, PI Emory University School of Medicine	DDE**	Plasma	221 ADNI1 aliquot samples 211 Baseline PLA 10 replicates	Data uploaded on 11/12/2014
05/19/2014	Dr. Kaj Blennow, PI Clinical Neurochemistry Lab	Cerebrospinal fluid levels of neurogranin Neurofilament Light (NFL)	CSF	416 ADNI1 aliquot samples 400 Baseline CSFs 16 Replicates	Data uploaded on 8/20/2014
05/19/2014	Rima Kaddurah-Daouk, PI Duke University	Metabolic Pathways and Networks in Alzheimer's Disease	Serum	833 ADNI1 aliquot samples 813 Baseline SER 20 Replicates	Data uploaded on 8/14/2015
10/28/2013	Courtney Sutphen, PI Washington University Lab of Dr. Anne Fagan and David Holtzman	YKL-40 and VILIP-1 in Longitudinal CSF sample sets	CSF	612 ADNI1, GO, 2 longitudinal aliquot samples 597 CSFs 15 Replicates	Data uploaded on 7/15/2015

Week of 9/24/2012	Lee Honigsberg, PI Nicholas Lewin-Koh, Angus Nairn, Les Shaw, Dan Spellman, Kristin Wildsmith, co-investigators Steve Hoffmann, PhD Scientific Program Manager The FNIH Biomarkers Consortium	CSF proteomic study Caprion using mrm mass spectrometry	CSF	306 ADNI1 aliquot samples 290 Baseline CSFs 16 Replicates	Data uploaded on 4/04/2014
9/12/2012	Dr.Robert Nagele, PI UMDNJ	Autoantibody biomarkers for detection and diagnosis of Alzheimer's disease	Serum	100 ADNI1 aliquot samples 50 Baseline MCI 50 Baseline NL	Data uploaded on 11/1/2012
5/9/2012	Geoff Baird, PI Thomas Montine and Elaine Peskind, co-investigators University of Washington	Analyzing the CSF proteome with an oligonucleotide aptamer array	CSF and Plasma	727 ADNI1 aliquot samples 372 Baseline CSFs and matching 355 PLA	Samples forwarded to Jing Zhang, PI
1/17/2012	Lee Honigsberg Nicholas Lewin-Koh, Angus Nairn, Les Shaw, Dan Spellman, Kristin Wildsmith, co-Pis	Pilot Study CSF proteomics project Caprion using mrm mass spectrometry*	CSF	25 ADNI1 aliquot samples 20 Baseline CSFs: 10 AD, 10 NL and 5 aliquots of a CSF pool	Data uploaded on 4/04/2014 with previous Proteomic Study
9/26/2011	Mary J Savage, PI Dan Holder, co-PI Merck Judy Siuciak, PhD Scientific Program Manager The FNIH Biomarkers Consortium	BACE and sAPP in CSF	CSF	402 ADNI1 aliquot samples 382 Baseline CSF 20 Replicates	Data uploaded on 4/24/2012
8/9/2011	William Potter, PI Eve Pickering, Mitch Kling, Les Shaw, Fred Immerman, co- investigators Judy Siuciak, PhD Scientific Program Manager The FNIH Biomarkers Consortium	CSF proteomic study RBM*	CSF	317 ADNI1 aliquot samples 311 Baseline CSFs 16 Replicates	Data uploaded on 01/03/2012

3/24/2011	Jing Zhang, PI Harborview Medical Center University of Washington School of Medicine	ADNI RARC CSF Proteomic study	CSF	390 ADNI1 aliquot samples Baseline CSFs: 92 AD, 187 MCI, 111 NC	Data uploaded on 3/11/2013 and 7/12/2013
5/12/2010	<p>1. Holly Soares, PI (2010-2011)</p> <p>Pfizer Eve Pickering & Fred Immerman Statistical analyses</p> <p>William Potter, Max Kuhn, David Shera, Mats Ferm, Robert A Dean, Adam J Simon, Frank Swenson, Judy Siuciak, June Kaplow, Madhay Thambisetty, Panayiotis Zagouras, Walter Koroshetz, Hong Wan, John Q Trojanowski, Leslie M Shaw, co-Investigators</p> <p>David Lee Scientific Program Manager</p> <p>Judy Siuciak Scientific Program Manager The FNIH Biomarkers Consortium Foundation for the National Institutes of Health</p> <p>2. William Potter, PI (2011- 2013)</p> <p>Eve Pickering & Fred Immerman Statistical analyses Mitch Kling</p>	<p>Plasma proteomic study Rules Based Medicine (RBM)*</p> <p>CSF proteomic study RBM</p>	<p>Plasma</p> <p>CSF</p>	<p>1065 ADNI1 aliquot samples Baseline PLA: 394 MCI, 111 AD, 57 NL Year 1 PLA: 349 MCI, 98 AD, 56 NL</p> <p>317 ADNI1 aliquot samples 311 Baseline CSFs 16 Replicates</p>	<p>Plasma proteomics RBM study Nov 19, 2010</p> <p>CSF proteomics RBM study January 3, 2012</p>

3/1/2010	John A. McIntyre, PI St. Francis Hospital	Redox Reactive Autoantibodies in ADNI subjects RARC/study phase 2	Serum	90 ADNI1 aliquot samples Baseline SER: 30 NC, 30 MCI and 30 AD	Data uploaded on 07/21/2011
7/14/2009	John A. McIntyre, PI St. Francis Hospital	Redox Reactive Autoantibodies in ADNI subjects, RARC/study phase 1	Serum	18 ADNI1 aliquot samples Baseline SER: 6 NC, 6 MCI and 6 AD	Data uploaded on 11/29/2009
7/13/2009	Lucas Restrepo, PI UCLA	Immuno signature of Alzheimer's Disease: using a blood plasma test	Plasma	100 ADNI1 aliquot samples Baseline PLA: 50 AD & 50 NL	Study not done due to lack of funding
12/4/2007	Andy Saykin, PI (2007- 2009) Dietrich Stephan, co-PI Indiana University Steven Potkin, PI (2007- 2009) UC Irvine Andrew Saykin, co-PI Indiana University	Whole genome analysis of ADNI1 cohort following DNA extraction(at Cogenics) Genetic association analysis of the ADNI 1 cohort	Whole blood	807 ADNI1 aliquot samples ADNI 1 Screening/Visit1 ApoE residual samples	Data uploaded on 3/16/2009

*PPSB Proteomic studies

** DDE, a metabolite of pesticide DDT (dichloro-diphenyl-trichloroethane)

Type of Sample Shipped	Total # Aliquots Shipped
CSF	3618
Plasma	2336
Serum	1041
Whole Blood	807
Total Shipped	7802

Summary of CSF, Plasma, Serum, Whole Blood Aliquots shipped out. The table above is a description of aliquots that were sent out to other investigators in the past 9 years (2007 through 2016). A total of 3618 CSF aliquots, 2336 plasma aliquots, 1041 serum aliquots, and 807 whole blood samples have been shipped out to these investigators.

*****GRAND TOTAL of prepared CSF, Plasma, and Serum Aliquots: 325,858**

Summary of Plasma aliquots use for Luminex runs




Figure 6. Graph of Summary of Plasma Aliquots used for Luminex runs

Number of Plasma Aliquots Used for Luminex				
Visit	ADNI 1	ADNI GO	ADNI 2	Total
BL	583	0	0	583
M6	16	0	0	16
M12	596	0	0	596
M18	17	0	0	17
M24	437	0	0	437
M36	184	0	0	184
M48	8	0	0	8
M60	0	0	0	0
M72	0	0	0	0
M84	0	0	0	0
Total	1841	0	0	1841

Table 6. Summary of Plasma aliquots used for Luminex runs.

Both Figure 6 and Table 6 provide a description of the plasma aliquots that were used for luminex runs. In total, 1841 plasma aliquots from ADNI 1 have been analyzed as of Jan.28th, 2016.

Subjects Providing Plasma at Baseline and Year 1 Follow-Up in ADNI DOD (Graph)




Figure 7. Percentage of subjects who provided Plasma at Baseline in ADNI DOD. The figure above compares the percentage of those enrolled in ADNI DOD who provided CSFs at Baseline. As of **January 28th, 2016** (cut-off date used for this report), approximately 84.38% of ADNI DOD subjects provided plasma samples at baseline and 40.63% at year 1 follow-up.

Subjects Providing Plasma at Baseline and Year 1 Follow-Up in each ADNI DOD (Table)

Summary Table of Percentage of subjects providing Plasma samples within ADNI DOD at Baseline and at 1 year Follow-Up

	Baseline			Year 1 Follow-Up	
ADNI Group	Number of Subjects enrolled as of <u>1/28/2016</u>	Number who provided Plasma as of <u>1/28/2016</u>	% who provided Plasma	Number who provided Plasma as of <u>1/28/2016</u>	% who provided Plasma
ADNI DOD	160	135	84.38%	65	40.63%

Table 7. Summary Table of Percentage of subjects providing Plasma samples within ADNI DOD at Baseline and at 1 year Follow-Up. This is a summary table for Figure 7, detailing the number and percent of subjects providing plasma samples within ADNI DOD, as well as the number of those who provided plasma samples at 1 year follow-up as of **1/28/2016**.

Prepared Aliquots from Originally Received Plasma Samples for ADNI DOD at BL and Follow-Up Visits (Graph)




Figure 8a. Comparison of the number of Prepared Aliquots from Originally Received Plasma Samples for ADNI DOD at Baseline and Yr 1. The graph above displays the number of subjects who have provided Plasma samples during the ADNI DOD at baseline and at Year 1 follow-up visit. We originally received between 16 and 20 plasma aliquots per subject from 86 individuals at baseline and 40 from Year 1 follow-up visit.

Prepared Aliquots from Originally Received Plasma Samples ADNI DOD at BL and Year 1 Follow-Up (Table)

Summary Table of Originally Received Plasma Aliquots from subjects at Baseline and at Yr 1 Follow-Up visit in ADNI DOD

ADNI DOD - <u>Originally Received</u>		
Number of Plasma Aliquots	BL	Yr 1 Follow-Up
0	0	0
1 to 5	0	0
6 to 10	3	0
11 to 15	38	22
16 to 20	86	40
21 to 25	6	3
26 to 30	2	0
31 to 35	0	0
36 to 40	0	0
41 to 45	0	0
46 to 50	0	0
Total	135	65

Table 8b. Summary Table of the number of Prepared Aliquots from Originally Received Plasma Samples from subjects at Baseline and at Yr 1 Follow-Up visits in ADNI DOD. This is a summary table corresponding to Figure 8a, detailing the number of subjects who provided plasma samples at baseline in ADNI DOD as well as at year 1 follow-up visit.

Currently Available Prepared Plasma Aliquots for ADNI DOD at BL and Year1 Follow-Up (Graph)




Figure 9a. Number of Currently Available Prepared Plasma Aliquots for ADNI DOD at Baseline and Yr 1 Follow-Up Visit. The graph above displays the number of subjects who have provided plasma samples during the ADNI DOD at baseline and at Year 1 follow-up visit. We currently have between 16 and 20 plasma aliquots per subject from 86 individuals at baseline and 40 from Year 1 follow-up visit.

Currently Available Prepared Plasma Aliquots for ADNIDOD at BL and Year 1 Follow-Up (Table)

Summary Table of Subjects providing Plasma samples at Baseline and at Yr 1 Follow-Up visit in ADNIDOD

ADNIDOD - <u>Currently Available</u>		
Number of Plasma Aliquots	BL	Yr 1 Follow-Up
0	0	0
1 to 5	0	0
6 to 10	3	0
11 to 15	38	22
16 to 20	86	40
21 to 25	6	3
26 to 30	2	0
31 to 35	0	0
36 to 40	0	0
41 to 45	0	0
46 to 50	0	0
Total	135	65

Table 9b. Summary Table of Currently Available Prepared Plasma aliquots at Baseline and at Yr 1 Follow-Up visit in ADNIDOD. This is a summary table corresponding to Figure 9b, detailing the number of subjects who provided plasma samples at baseline in ADNIDOD as well as at Year1 follow-up visits.